Refers to a compound of formula (i), wherein R1 is piperidinilo, piridilo, among others, is - Cf3 - R7, R8 is selected CHF2 (ii) the figure, R9 IS BR, CL, F, among others. Is the preferred Compound (4 - (5 - (3,4-dimethoxyphenyl) - 7 - (trifluoromethyl) - also tetrahidropirazolo - [1,5-a] pyrimidin-2-yl) - 2 - (IL) phenyl) piperazin-1-yl) methanone.This Compound acts as an antagonist or inhibitor of Toll receptors similar to 7 and \/ or 8, and to their use in Pharmaceutical compositions effective for the treatment of systemic lupus erythematosus (SLE) and lupus nephritisSE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE R1 ES PIPERIDINILO, PIRIDILO, ENTRE OTROS R7 ES -CF3, -CHF2 R8 SE SELECCIONA DE LA FIGURA (II), R9 ES BR, CL, F, ENTRE OTROS. ES COMPUESTO PREFERIDO (4-(5-(3,4-DIMETOXIFENIL)-7-(TRIFLUOROMETIL)-4,5,6,7-TETRAHIDROPIRAZOLO[1,5-A]PIRIMIDIN-2-IL)FENIL)(PIPERAZIN-1-IL ) METANONA. DICHO COMPUESTO ACTUA COMO ANTAGONISTA O INHIBIDOR DE RECEPTORES SIMILARES A TOLL 7 Y/U 8, Y CON SU USO EN COMPOSICIONES FARMACEUTICAS EFICACES PARA EL TRATAMIENTO DEL LUPUS ERITEMATOSO SISTEMICO (SLE) Y LA NEFRITIS POR LUPUS
